These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 34131969)

  • 1. Chilblain-like lesions after BNT162b2 mRNA COVID-19 vaccine: a case report suggesting that 'COVID toes' are due to the immune reaction to SARS-CoV-2.
    Lesort C; Kanitakis J; Donzier L; Jullien D
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):e630-e632. PubMed ID: 34131969
    [No Abstract]   [Full Text] [Related]  

  • 2. 'Blue toes' following vaccination with the BNT162b2 mRNA COVID-19 vaccine.
    Davido B; Mascitti H; Fortier-Beaulieu M; Jaffal K; de Truchis P
    J Travel Med; 2021 Jun; 28(4):. PubMed ID: 33620081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BNT162b2 mRNA COVID-19 vaccine-induced chilblain-like lesions reinforces the hypothesis of their relationship with SARS-CoV-2.
    Piccolo V; Bassi A; Argenziano G; Mazzatenta C; Cutrone M; Neri I; Grimalt R; Russo T
    J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):e493-e494. PubMed ID: 33914966
    [No Abstract]   [Full Text] [Related]  

  • 4. Chilblain-like lesions onset during SARS-CoV-2 infection in a COVID-19-vaccinated adolescent: case report and review of literature.
    Paparella R; Tarani L; Properzi E; Costantino F; Saburri C; Lucibello R; Richetta A; Spalice A; Leonardi L
    Ital J Pediatr; 2022 Jun; 48(1):93. PubMed ID: 35698236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [COVID-toes, a cutaneous sign of innate resistance to SARS-CoV-2].
    Yatim A; Gilliet M
    Rev Med Suisse; 2021 Mar; 17(732):646-652. PubMed ID: 33793103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bilateral Chilblain-like Lesions of the Toes Characterized by Microvascular Remodeling in Adolescents During the COVID-19 Pandemic.
    Discepolo V; Catzola A; Pierri L; Mascolo M; Della Casa F; Vastarella M; Smith G; Travaglino A; Punziano A; Nappa P; Staibano S; Bruzzese E; Fabbrocini G; Guarino A; Alessio M
    JAMA Netw Open; 2021 Jun; 4(6):e2111369. PubMed ID: 34110396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Not only toes and fingers: COVID vaccine-induced chilblain-like lesions of the knees.
    Bassi A; Mazzatenta C; Sechi A; Cutrone M; Piccolo V
    J Eur Acad Dermatol Venereol; 2022 Jul; 36(7):e497-e498. PubMed ID: 35188988
    [No Abstract]   [Full Text] [Related]  

  • 8. Chilblain lesions after COVID-19 mRNA vaccine.
    Pileri A; Guglielmo A; Raone B; Patrizi A
    Br J Dermatol; 2021 Jul; 185(1):e3. PubMed ID: 33904168
    [No Abstract]   [Full Text] [Related]  

  • 9. Pediatric COVID toes and fingers.
    Koschitzky M; Oyola RR; Lee-Wong M; Abittan B; Silverberg N
    Clin Dermatol; 2021; 39(1):84-91. PubMed ID: 33972057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout.
    Zaqout A; Daghfal J; Alaqad I; Hussein SAN; Aldushain A; Almaslamani MA; Abukhattab M; Omrani AS
    Int J Infect Dis; 2021 Jul; 108():116-118. PubMed ID: 33992763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A first case of 'Covid toes' from a viral vector-based COVID-19 vaccine.
    Van Loon A; Mortelmans D; Siozopoulou V; Ogunjimi B; Jansens H; Lambert J; Aerts O
    J Eur Acad Dermatol Venereol; 2022 Jun; 36(6):e400-e402. PubMed ID: 35067975
    [No Abstract]   [Full Text] [Related]  

  • 12. "COVID Toes" After mRNA COVID-19 Vaccines.
    Kelso JM; Coda AB; Keating RM; Vaccari DM
    J Allergy Clin Immunol Pract; 2021 Aug; 9(8):3196-3197. PubMed ID: 34162525
    [No Abstract]   [Full Text] [Related]  

  • 13. Chilblain-like lesions with prominent bullae in a patient with COVID-19.
    Rubin A; Alamgir M; Rubin J; Rao BK
    BMJ Case Rep; 2020 Nov; 13(11):. PubMed ID: 33139373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type I Interferon Signature in Chilblains Following SARS-CoV-2 mRNA Vaccine: A Case Report.
    Souaid K; Oulès B; Sohier P; Deschamps L; Aractingi S; Dupin N
    Acta Derm Venereol; 2021 Nov; 101(11):adv00589. PubMed ID: 34396420
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of BNT162b2 (Pfizer-BioNtech) and mRNA-1273 (Moderna) SARS-CoV-2 mRNA vaccine immunogenicity in dialysis patients.
    Kaiser RA; Haller MC; Apfalter P; Kerschner H; Cejka D
    Kidney Int; 2021 Sep; 100(3):697-698. PubMed ID: 34270945
    [No Abstract]   [Full Text] [Related]  

  • 16. Experience with SARS-CoV-2 BNT162b2 mRNA vaccine in dialysis patients.
    Yanay NB; Freiman S; Shapira M; Wishahi S; Hamze M; Elhaj M; Zaher M; Armaly Z
    Kidney Int; 2021 Jun; 99(6):1496-1498. PubMed ID: 33887318
    [No Abstract]   [Full Text] [Related]  

  • 17. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    Skowronski DM; De Serres G
    N Engl J Med; 2021 Apr; 384(16):1576-1577. PubMed ID: 33596348
    [No Abstract]   [Full Text] [Related]  

  • 18. Going viral: A brief history of Chilblain-like skin lesions ("COVID toes") amidst the COVID-19 pandemic.
    Massey PR; Jones KM
    Semin Oncol; 2020 Oct; 47(5):330-334. PubMed ID: 32736881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.
    Absalon J; Koury K; Gruber WC
    N Engl J Med; 2021 Apr; 384(16):1578. PubMed ID: 33596351
    [No Abstract]   [Full Text] [Related]  

  • 20. Chilblain-Like Lesions (CLL) Associated With COVID-19 ("COVID Toes"): A Systematic Review.
    Kashetsky N; Mukovozov IM; Bergman J
    J Cutan Med Surg; 2021; 25(6):627-633. PubMed ID: 33849305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.